CA2543058A1 - Mouches transgeniques exprimant un mutant a.beta.42 - Google Patents
Mouches transgeniques exprimant un mutant a.beta.42 Download PDFInfo
- Publication number
- CA2543058A1 CA2543058A1 CA002543058A CA2543058A CA2543058A1 CA 2543058 A1 CA2543058 A1 CA 2543058A1 CA 002543058 A CA002543058 A CA 002543058A CA 2543058 A CA2543058 A CA 2543058A CA 2543058 A1 CA2543058 A1 CA 2543058A1
- Authority
- CA
- Canada
- Prior art keywords
- fly
- transgenic
- phenotype
- transgenic fly
- drosophila
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000009261 transgenic effect Effects 0.000 title claims abstract description 184
- 238000000034 method Methods 0.000 claims abstract description 91
- 108010026424 tau Proteins Proteins 0.000 claims abstract description 89
- 102000013498 tau Proteins Human genes 0.000 claims abstract description 86
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 73
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 22
- 230000014509 gene expression Effects 0.000 claims description 82
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 claims description 71
- 230000035772 mutation Effects 0.000 claims description 50
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 49
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 45
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 33
- 230000004770 neurodegeneration Effects 0.000 claims description 25
- 229920001184 polypeptide Polymers 0.000 claims description 22
- 230000001418 larval effect Effects 0.000 claims description 19
- 230000003137 locomotive effect Effects 0.000 claims description 19
- 230000003542 behavioural effect Effects 0.000 claims description 16
- 230000004064 dysfunction Effects 0.000 claims description 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 abstract description 79
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 29
- 102000004169 proteins and genes Human genes 0.000 abstract description 21
- 150000001875 compounds Chemical class 0.000 abstract description 14
- 230000002068 genetic effect Effects 0.000 abstract description 9
- 238000012216 screening Methods 0.000 abstract description 8
- 239000003607 modifier Substances 0.000 abstract description 4
- 239000002243 precursor Substances 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 241000255925 Diptera Species 0.000 description 81
- 239000003795 chemical substances by application Substances 0.000 description 63
- 239000013598 vector Substances 0.000 description 43
- 108700019146 Transgenes Proteins 0.000 description 41
- 210000001519 tissue Anatomy 0.000 description 32
- 230000033001 locomotion Effects 0.000 description 25
- 238000007514 turning Methods 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 20
- 230000008859 change Effects 0.000 description 19
- 108020004414 DNA Proteins 0.000 description 18
- 239000003814 drug Substances 0.000 description 18
- 239000003623 enhancer Substances 0.000 description 18
- 238000011161 development Methods 0.000 description 16
- 230000018109 developmental process Effects 0.000 description 16
- 102100039556 Galectin-4 Human genes 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 230000009466 transformation Effects 0.000 description 14
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 13
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 13
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 13
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 13
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 230000001537 neural effect Effects 0.000 description 13
- 235000019645 odor Nutrition 0.000 description 13
- 229940124597 therapeutic agent Drugs 0.000 description 13
- 206010012289 Dementia Diseases 0.000 description 12
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 12
- 210000004556 brain Anatomy 0.000 description 12
- 230000009194 climbing Effects 0.000 description 12
- 150000007523 nucleic acids Chemical group 0.000 description 12
- 210000003169 central nervous system Anatomy 0.000 description 11
- 230000007850 degeneration Effects 0.000 description 11
- 239000003550 marker Substances 0.000 description 11
- 230000000750 progressive effect Effects 0.000 description 11
- 238000013459 approach Methods 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 210000000056 organ Anatomy 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 201000011240 Frontotemporal dementia Diseases 0.000 description 8
- 108010029485 Protein Isoforms Proteins 0.000 description 8
- 102000001708 Protein Isoforms Human genes 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 210000002257 embryonic structure Anatomy 0.000 description 8
- 150000003384 small molecules Chemical class 0.000 description 8
- 238000012549 training Methods 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 206010017577 Gait disturbance Diseases 0.000 description 7
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 7
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 7
- 210000002569 neuron Anatomy 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 241000255601 Drosophila melanogaster Species 0.000 description 6
- 101000891579 Homo sapiens Microtubule-associated protein tau Proteins 0.000 description 6
- 230000002159 abnormal effect Effects 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 230000006735 deficit Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 230000002018 overexpression Effects 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000000151 deposition Methods 0.000 description 5
- 230000008021 deposition Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 230000000877 morphologic effect Effects 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 210000001082 somatic cell Anatomy 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 108091006106 transcriptional activators Proteins 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 description 4
- 101100268551 Drosophila melanogaster Appl gene Proteins 0.000 description 4
- 101000823051 Homo sapiens Amyloid-beta precursor protein Proteins 0.000 description 4
- 102220606690 Neurotrimin_D23N_mutation Human genes 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 235000019789 appetite Nutrition 0.000 description 4
- 230000036528 appetite Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000009187 flying Effects 0.000 description 4
- 210000004602 germ cell Anatomy 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 210000003128 head Anatomy 0.000 description 4
- 102000057063 human MAPT Human genes 0.000 description 4
- 150000002484 inorganic compounds Chemical class 0.000 description 4
- 229910010272 inorganic material Inorganic materials 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 230000013016 learning Effects 0.000 description 4
- 230000037023 motor activity Effects 0.000 description 4
- 210000000653 nervous system Anatomy 0.000 description 4
- 150000002894 organic compounds Chemical class 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 230000000392 somatic effect Effects 0.000 description 4
- 238000011830 transgenic mouse model Methods 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 3
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 3
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 3
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 108700024394 Exon Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102000029749 Microtubule Human genes 0.000 description 3
- 108091022875 Microtubule Proteins 0.000 description 3
- 102100040243 Microtubule-associated protein tau Human genes 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 208000027089 Parkinsonian disease Diseases 0.000 description 3
- 206010034010 Parkinsonism Diseases 0.000 description 3
- 108010067902 Peptide Library Proteins 0.000 description 3
- 102000029797 Prion Human genes 0.000 description 3
- 108091000054 Prion Proteins 0.000 description 3
- 108090000820 Rhodopsin Proteins 0.000 description 3
- 102220538768 Superoxide dismutase [Cu-Zn]_E22G_mutation Human genes 0.000 description 3
- 230000001133 acceleration Effects 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000013599 cloning vector Substances 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 101150000123 elav gene Proteins 0.000 description 3
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 102000046783 human APP Human genes 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000007758 mating behavior Effects 0.000 description 3
- 230000015654 memory Effects 0.000 description 3
- 210000004688 microtubule Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 208000005264 motor neuron disease Diseases 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 230000002232 neuromuscular Effects 0.000 description 3
- 210000000158 ommatidium Anatomy 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000002320 spinal muscular atrophy Diseases 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 208000037259 Amyloid Plaque Diseases 0.000 description 2
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 2
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 2
- 101100125027 Dictyostelium discoideum mhsp70 gene Proteins 0.000 description 2
- 201000010374 Down Syndrome Diseases 0.000 description 2
- 241000255582 Drosophilidae Species 0.000 description 2
- 101150077230 GAL4 gene Proteins 0.000 description 2
- 108010001515 Galectin 4 Proteins 0.000 description 2
- 208000003736 Gerstmann-Straussler-Scheinker Disease Diseases 0.000 description 2
- 206010072075 Gerstmann-Straussler-Scheinker syndrome Diseases 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 101150031823 HSP70 gene Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 208000027747 Kennedy disease Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 240000000233 Melia azedarach Species 0.000 description 2
- 101710115937 Microtubule-associated protein tau Proteins 0.000 description 2
- 206010069681 Monomelic amyotrophy Diseases 0.000 description 2
- 208000001089 Multiple system atrophy Diseases 0.000 description 2
- 206010068871 Myotonic dystrophy Diseases 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- 208000008457 Neurologic Manifestations Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 108010001441 Phosphopeptides Proteins 0.000 description 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 2
- 208000000474 Poliomyelitis Diseases 0.000 description 2
- 102000015499 Presenilins Human genes 0.000 description 2
- 108010050254 Presenilins Proteins 0.000 description 2
- 208000024777 Prion disease Diseases 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 108090000848 Ubiquitin Proteins 0.000 description 2
- 102000044159 Ubiquitin Human genes 0.000 description 2
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 229910002056 binary alloy Inorganic materials 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 230000009193 crawling Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 101150052825 dnaK gene Proteins 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000013861 fat-free Nutrition 0.000 description 2
- 239000012847 fine chemical Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 210000000087 hemolymph Anatomy 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 230000006742 locomotor activity Effects 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 108091008695 photoreceptors Proteins 0.000 description 2
- 108010040003 polyglutamine Proteins 0.000 description 2
- 229920000155 polyglutamine Polymers 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 230000007101 progressive neurodegeneration Effects 0.000 description 2
- 230000000384 rearing effect Effects 0.000 description 2
- 102200158871 rs33955330 Human genes 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- -1 small molecules Chemical class 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000002739 subcortical effect Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000005026 transcription initiation Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 1
- 102100027831 14-3-3 protein theta Human genes 0.000 description 1
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 1
- MQWCXKGKQLNYQG-UHFFFAOYSA-N 4-methylcyclohexan-1-ol Chemical compound CC1CCC(O)CC1 MQWCXKGKQLNYQG-UHFFFAOYSA-N 0.000 description 1
- 108091092742 A-DNA Proteins 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 241001156002 Anthonomus pomorum Species 0.000 description 1
- 101150022237 Appl gene Proteins 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 102000007371 Ataxin-3 Human genes 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 230000007082 Aβ accumulation Effects 0.000 description 1
- 208000034577 Benign intracranial hypertension Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 description 1
- 241000208199 Buxus sempervirens Species 0.000 description 1
- 101100468275 Caenorhabditis elegans rep-1 gene Proteins 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102000012437 Copper-Transporting ATPases Human genes 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 description 1
- 208000009093 Diffuse Neurofibrillary Tangles with Calcification Diseases 0.000 description 1
- 108700024228 Drosophila Ser Proteins 0.000 description 1
- 241000255537 Drosophila albomicans Species 0.000 description 1
- 241000031072 Drosophila annulipes Species 0.000 description 1
- 241000867621 Drosophila atripex Species 0.000 description 1
- 241000216231 Drosophila auraria Species 0.000 description 1
- 241000976284 Drosophila baimaii Species 0.000 description 1
- 241000573218 Drosophila biarmipes Species 0.000 description 1
- 241001246245 Drosophila biauraria Species 0.000 description 1
- 241000255587 Drosophila bifasciata Species 0.000 description 1
- 241000205064 Drosophila birchii Species 0.000 description 1
- 241001478415 Drosophila bocki Species 0.000 description 1
- 241001278362 Drosophila bocqueti Species 0.000 description 1
- 241000976288 Drosophila burlai Species 0.000 description 1
- 108700013637 Drosophila bw Proteins 0.000 description 1
- 241000031075 Drosophila curviceps Species 0.000 description 1
- 241000981772 Drosophila daruma Species 0.000 description 1
- 108700011319 Drosophila egg Proteins 0.000 description 1
- 241000529875 Drosophila eohydei Species 0.000 description 1
- 241000142780 Drosophila ercepeae Species 0.000 description 1
- 241000255604 Drosophila erecta Species 0.000 description 1
- 241001157800 Drosophila eugracilis Species 0.000 description 1
- 241000255445 Drosophila falleni Species 0.000 description 1
- 241000031081 Drosophila formosana Species 0.000 description 1
- 241000255606 Drosophila funebris Species 0.000 description 1
- 241000923638 Drosophila fuyamai Species 0.000 description 1
- 241001478405 Drosophila gunungcola Species 0.000 description 1
- 241000933870 Drosophila guttifera Species 0.000 description 1
- 241000255597 Drosophila hydei Species 0.000 description 1
- 241000027196 Drosophila hypocausta Species 0.000 description 1
- 241000180020 Drosophila imaii Species 0.000 description 1
- 241000157043 Drosophila jambulina Species 0.000 description 1
- 241000488534 Drosophila kanekoi Species 0.000 description 1
- 241000967797 Drosophila khaoyana Species 0.000 description 1
- 241001414876 Drosophila kikkawai Species 0.000 description 1
- 241000018444 Drosophila kohkoa Species 0.000 description 1
- 241000264437 Drosophila lacertosa Species 0.000 description 1
- 241000946921 Drosophila lacteicornis Species 0.000 description 1
- 241001559016 Drosophila leontia Species 0.000 description 1
- 108700019186 Drosophila lin Proteins 0.000 description 1
- 241001278357 Drosophila lini Species 0.000 description 1
- 241000498611 Drosophila lutescens Species 0.000 description 1
- 241001474306 Drosophila malerkotliana malerkotliana Species 0.000 description 1
- 241001188675 Drosophila malerkotliana pallens Species 0.000 description 1
- 241000255598 Drosophila mauritiana Species 0.000 description 1
- 241000967764 Drosophila mayri Species 0.000 description 1
- 241000255269 Drosophila melanica Species 0.000 description 1
- 241001414879 Drosophila mimetica Species 0.000 description 1
- 241000063354 Drosophila multispina Species 0.000 description 1
- 241000142781 Drosophila nasuta Species 0.000 description 1
- 241000255461 Drosophila nebulosa Species 0.000 description 1
- 241000031079 Drosophila neohypocausta Species 0.000 description 1
- 241001674532 Drosophila neonasuta Species 0.000 description 1
- 241001516539 Drosophila nigromaculata Species 0.000 description 1
- 241000157929 Drosophila niveifrons Species 0.000 description 1
- 241000255322 Drosophila orena Species 0.000 description 1
- 241000372026 Drosophila palustris Species 0.000 description 1
- 241001114024 Drosophila parabipectinata Species 0.000 description 1
- 241001114023 Drosophila paralutea Species 0.000 description 1
- 241001235067 Drosophila paramelanica Species 0.000 description 1
- 241000967770 Drosophila parvula Species 0.000 description 1
- 241000205335 Drosophila paulistorum Species 0.000 description 1
- 241001130488 Drosophila pectinifera Species 0.000 description 1
- 241000255520 Drosophila phalerata Species 0.000 description 1
- 241000358027 Drosophila prostipennis Species 0.000 description 1
- 241001188674 Drosophila pseudoananassae nigrens Species 0.000 description 1
- 241000923646 Drosophila pseudoananassae pseudoananassae Species 0.000 description 1
- 241000018446 Drosophila pulaua Species 0.000 description 1
- 241001116793 Drosophila pulchrella Species 0.000 description 1
- 241000946923 Drosophila quadraria Species 0.000 description 1
- 241000543873 Drosophila quadrilineata Species 0.000 description 1
- 241000692303 Drosophila repletoides Species 0.000 description 1
- 241000255243 Drosophila robusta Species 0.000 description 1
- 241000946946 Drosophila rufa Species 0.000 description 1
- 241000255467 Drosophila saltans Species 0.000 description 1
- 241000255317 Drosophila sechellia Species 0.000 description 1
- 241001265506 Drosophila seguyi Species 0.000 description 1
- 241000031083 Drosophila siamana Species 0.000 description 1
- 241000255345 Drosophila simulans Species 0.000 description 1
- 241000546279 Drosophila sordidula Species 0.000 description 1
- 241001414872 Drosophila sturtevanti Species 0.000 description 1
- 241000967796 Drosophila subauraria Species 0.000 description 1
- 241000372036 Drosophila subpalustris Species 0.000 description 1
- 241000033745 Drosophila sulfurigaster albostrigata Species 0.000 description 1
- 241000033744 Drosophila sulfurigaster bilimbata Species 0.000 description 1
- 241001136566 Drosophila suzukii Species 0.000 description 1
- 241001157809 Drosophila takahashii Species 0.000 description 1
- 241000255354 Drosophila teissieri Species 0.000 description 1
- 241000358024 Drosophila trapezifrons Species 0.000 description 1
- 241000946949 Drosophila triauraria Species 0.000 description 1
- 241000358016 Drosophila trilutea Species 0.000 description 1
- 241000981773 Drosophila ustulata Species 0.000 description 1
- 241001414914 Drosophila varians Species 0.000 description 1
- 241000255352 Drosophila virilis Species 0.000 description 1
- 108700013639 Drosophila w Proteins 0.000 description 1
- 241000358011 Drosophila watanabei Species 0.000 description 1
- 241000255293 Drosophila willistoni Species 0.000 description 1
- 241000255334 Drosophila yakuba Species 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101000854943 Enterobacteria phage T4 Valyl-tRNA ligase modifier Proteins 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- 206010018341 Gliosis Diseases 0.000 description 1
- 102100033495 Glycine dehydrogenase (decarboxylating), mitochondrial Human genes 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 241000405147 Hermes Species 0.000 description 1
- 101100268553 Homo sapiens APP gene Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000018127 Idiopathic intracranial hypertension Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 208000006264 Korsakoff syndrome Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 208000002569 Machado-Joseph Disease Diseases 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 208000026072 Motor neurone disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 208000002033 Myoclonus Diseases 0.000 description 1
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 1
- 208000009905 Neurofibromatoses Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 208000014060 Niemann-Pick disease Diseases 0.000 description 1
- 208000035544 Nonketotic hyperglycinaemia Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 206010033892 Paraplegia Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010043958 Peptoids Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 108010068086 Polyubiquitin Proteins 0.000 description 1
- 102100037935 Polyubiquitin-C Human genes 0.000 description 1
- 241001599645 Ponera <ant> Species 0.000 description 1
- 206010057244 Post viral fatigue syndrome Diseases 0.000 description 1
- 208000036757 Postencephalitic parkinsonism Diseases 0.000 description 1
- 208000010366 Postpoliomyelitis syndrome Diseases 0.000 description 1
- 208000032319 Primary lateral sclerosis Diseases 0.000 description 1
- 208000033526 Proximal spinal muscular atrophy type 3 Diseases 0.000 description 1
- 241000382353 Pupa Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 208000006289 Rett Syndrome Diseases 0.000 description 1
- 102000004330 Rhodopsin Human genes 0.000 description 1
- 208000021811 Sandhoff disease Diseases 0.000 description 1
- 102000054727 Serum Amyloid A Human genes 0.000 description 1
- 108700028909 Serum Amyloid A Proteins 0.000 description 1
- 208000032930 Spastic paraplegia Diseases 0.000 description 1
- 208000003954 Spinal Muscular Atrophies of Childhood Diseases 0.000 description 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 1
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 108010027912 Sulfite Oxidase Proteins 0.000 description 1
- 102000043440 Sulfite oxidase Human genes 0.000 description 1
- 208000027522 Sydenham chorea Diseases 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- 208000034799 Tauopathies Diseases 0.000 description 1
- 208000022292 Tay-Sachs disease Diseases 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 101710195626 Transcriptional activator protein Proteins 0.000 description 1
- 102000008579 Transposases Human genes 0.000 description 1
- 108010020764 Transposases Proteins 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000030451 Vascular dementia disease Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 description 1
- 208000018839 Wilson disease Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 108091006088 activator proteins Proteins 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 101150031224 app gene Proteins 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000035045 associative learning Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000006736 behavioral deficit Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- XMQFTWRPUQYINF-UHFFFAOYSA-N bensulfuron-methyl Chemical compound COC(=O)C1=CC=CC=C1CS(=O)(=O)NC(=O)NC1=NC(OC)=CC(OC)=N1 XMQFTWRPUQYINF-UHFFFAOYSA-N 0.000 description 1
- 108091007737 beta-secretases Proteins 0.000 description 1
- 239000007998 bicine buffer Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000002060 circadian Effects 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000011508 cuticle pigmentation Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 208000017004 dementia pugilistica Diseases 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 230000032669 eclosion Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 201000006517 essential tremor Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004373 eye development Effects 0.000 description 1
- 201000006061 fatal familial insomnia Diseases 0.000 description 1
- 230000004634 feeding behavior Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 102000038383 gamma-secretases Human genes 0.000 description 1
- 108091007739 gamma-secretases Proteins 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 230000007387 gliosis Effects 0.000 description 1
- 201000011205 glycine encephalopathy Diseases 0.000 description 1
- 230000003370 grooming effect Effects 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000001153 interneuron Anatomy 0.000 description 1
- 201000004815 juvenile spinal muscular atrophy Diseases 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 206010023497 kuru Diseases 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 208000036546 leukodystrophy Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000006738 locomotor deficit Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003446 memory effect Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 208000027061 mild cognitive impairment Diseases 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 201000004931 neurofibromatosis Diseases 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000031237 olivopontocerebellar atrophy Diseases 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 208000002593 pantothenate kinase-associated neurodegeneration Diseases 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 230000001769 paralizing effect Effects 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 210000000608 photoreceptor cell Anatomy 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 208000000170 postencephalitic Parkinson disease Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 201000002241 progressive bulbar palsy Diseases 0.000 description 1
- 201000008752 progressive muscular atrophy Diseases 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 208000001381 pseudotumor cerebri Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 102200131541 rs121912450 Human genes 0.000 description 1
- 102220092852 rs754853086 Human genes 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 208000037959 spinal tumor Diseases 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 208000003755 striatonigral degeneration Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- FRGKKTITADJNOE-UHFFFAOYSA-N sulfanyloxyethane Chemical compound CCOS FRGKKTITADJNOE-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 208000032527 type III spinal muscular atrophy Diseases 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 230000001720 vestibular Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 210000003032 wing Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/033—Rearing or breeding invertebrates; New breeds of invertebrates
- A01K67/0333—Genetically modified invertebrates, e.g. transgenic, polyploid
- A01K67/0337—Genetically modified Arthropods
- A01K67/0339—Genetically modified insects, e.g. Drosophila melanogaster, medfly
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8114—Kunitz type inhibitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/70—Invertebrates
- A01K2227/706—Insects, e.g. Drosophila melanogaster, medfly
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0312—Animal model for Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Environmental Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (21)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51291303P | 2003-10-20 | 2003-10-20 | |
| US51315203P | 2003-10-21 | 2003-10-21 | |
| US51297003P | 2003-10-21 | 2003-10-21 | |
| US51297203P | 2003-10-21 | 2003-10-21 | |
| US51314903P | 2003-10-21 | 2003-10-21 | |
| US60/513,149 | 2003-10-21 | ||
| US60/513,152 | 2003-10-21 | ||
| US60/512,970 | 2003-10-21 | ||
| US60/512,972 | 2003-10-21 | ||
| US60/512,913 | 2003-10-21 | ||
| US10/852,892 | 2004-05-25 | ||
| US10/852,951 | 2004-05-25 | ||
| US10/852,892 US20040244064A1 (en) | 2003-10-20 | 2004-05-25 | Transgenic flies expressing Abeta42-Flemish |
| US10/852,974 US20050108779A1 (en) | 2003-10-21 | 2004-05-25 | Transgenic flies expressing Abeta42-Italian |
| US10/852,951 US20040255341A1 (en) | 2003-10-21 | 2004-05-25 | Transgenic flies expressing Abeta42-Arctic |
| US10/852,973 | 2004-05-25 | ||
| US10/852,973 US20040255342A1 (en) | 2003-10-21 | 2004-05-25 | Transgenic flies expressing Abeta42-Iowa |
| US10/852,974 | 2004-05-25 | ||
| US10/853,593 | 2004-05-25 | ||
| US10/853,593 US20040250302A1 (en) | 2003-10-21 | 2004-05-25 | Transgenic flies expressing Abeta42-dutch |
| PCT/US2004/034838 WO2005041650A1 (fr) | 2003-10-20 | 2004-10-21 | Mouches transgeniques exprimant un mutant a$g(b)42 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2543058A1 true CA2543058A1 (fr) | 2005-05-12 |
Family
ID=34557951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002543058A Abandoned CA2543058A1 (fr) | 2003-10-20 | 2004-10-21 | Mouches transgeniques exprimant un mutant a.beta.42 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1684574A4 (fr) |
| AU (1) | AU2004284937A1 (fr) |
| CA (1) | CA2543058A1 (fr) |
| WO (1) | WO2005041650A1 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| PT1954718E (pt) | 2005-11-30 | 2014-12-16 | Abbvie Inc | Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos |
| CN101528770A (zh) * | 2005-11-30 | 2009-09-09 | 艾博特公司 | 制备重组形式的人β-淀粉样蛋白的方法和这些蛋白质的应用 |
| DK1976877T4 (en) | 2005-11-30 | 2017-01-16 | Abbvie Inc | Monoclonal antibodies to amyloid beta protein and uses thereof |
| AU2007261584A1 (en) * | 2006-06-16 | 2007-12-27 | Envivo Pharmaceutical Inc. | Transgenic flies expressing tau and amyloid precursor fragment |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| WO2008104386A2 (fr) | 2007-02-27 | 2008-09-04 | Abbott Gmbh & Co. Kg | Méthode de traitement d'amyloïdoses |
| MX360403B (es) | 2010-04-15 | 2018-10-31 | Abbvie Inc | Proteinas de union a amiloide beta. |
| EP2603524A1 (fr) | 2010-08-14 | 2013-06-19 | AbbVie Inc. | Protéines de liaison bêta-amyloïdes |
| GB201603654D0 (en) * | 2016-03-02 | 2016-04-13 | Parkure Ltd | Screening assay |
| JP6870852B2 (ja) * | 2017-05-19 | 2021-05-12 | 国立研究開発法人国立長寿医療研究センター | 遺伝子組換え無脊椎動物アルツハイマー病モデルおよびその利用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69229718D1 (de) * | 1992-03-20 | 1999-09-09 | Innogenetics Nv | Mutierte Form von dem Beta-Amyloidprecursor Proteine Gen |
| EP2082749A3 (fr) * | 2000-07-07 | 2010-06-30 | Bioarctic Neuroscience AB | Prévention et traitement de la maladie d'Alzheimer |
| US6900367B2 (en) * | 2000-09-29 | 2005-05-31 | Novartis | Transgenic Drosophila melanogaster expressing a β42 in the eye |
| US20040194158A1 (en) * | 2003-03-28 | 2004-09-30 | Baylor College Of Medicine | Model for neurodegenerative disorders |
| TWI343806B (en) * | 2003-07-01 | 2011-06-21 | Nat Health Research Institutes | Methods of inhibiting neurodegenerative disease |
-
2004
- 2004-10-21 WO PCT/US2004/034838 patent/WO2005041650A1/fr active Application Filing
- 2004-10-21 CA CA002543058A patent/CA2543058A1/fr not_active Abandoned
- 2004-10-21 EP EP04795934A patent/EP1684574A4/fr not_active Withdrawn
- 2004-10-21 AU AU2004284937A patent/AU2004284937A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005041650A1 (fr) | 2005-05-12 |
| EP1684574A1 (fr) | 2006-08-02 |
| AU2004284937A1 (en) | 2005-05-12 |
| EP1684574A4 (fr) | 2008-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080076145A1 (en) | Transgenic flies expressing tau and amyloid precursor fragment | |
| Hsiao | Transgenic mice expressing Alzheimer amyloid precursor proteins | |
| AU2004231527B2 (en) | Model for neurodegenerative disorders | |
| Berezovska et al. | The Alzheimer-related gene presenilin 1 facilitates notch 1 in primary mammalian neurons | |
| Crowther et al. | A Drosophila model of Alzheimer's disease | |
| WO2005117577A2 (fr) | Modele pour maladies neurodegeneratives | |
| CA2543058A1 (fr) | Mouches transgeniques exprimant un mutant a.beta.42 | |
| CA2596267A1 (fr) | Modeles poisson zebre de la maladie d'alzheimer | |
| US20050132424A1 (en) | Transgenic flies expressing Abeta42-Dutch | |
| Hwangbo et al. | Control of apoptosis by Drosophila DCAF12 | |
| US20050132425A1 (en) | Transgenic flies expressing Abeta42-Italian | |
| Dodart et al. | Overview on rodent models of Alzheimer's disease | |
| CA2590725A1 (fr) | Tri automatise d'animaux non humains, par sexe | |
| US20050132421A1 (en) | Transgenic flies expressing Abeta42-Arctic | |
| US20050132423A1 (en) | Transgenic flies expressing Abeta42-Flemish | |
| US20050132422A1 (en) | Transgenic flies expressing Abeta42-Iowa | |
| US20040250302A1 (en) | Transgenic flies expressing Abeta42-dutch | |
| US20040255341A1 (en) | Transgenic flies expressing Abeta42-Arctic | |
| US20040244064A1 (en) | Transgenic flies expressing Abeta42-Flemish | |
| US20040255342A1 (en) | Transgenic flies expressing Abeta42-Iowa | |
| Edwin Chan et al. | Drosophila models of polyglutamine diseases | |
| Mucke et al. | Contributions of the glial injury response to the multifactorial pathogenesis of Alzheimer’s disease | |
| Mucke | Contributions of the Glial Injury Response to the Multifactorial Pathogenesis of Alzheimer's Disease L. Mucke, M. Buttini, RW Mahley, RE Pitas, J. Raber, and T. Wyss-Coray | |
| Vorberg et al. | By DAMIAN C. CROWTHER, RICHARD PAGE, DHIANJALI CHANDRARATNA, and DAVID A. LOMAS | |
| Jackson | Modeling neurodegenerative diseases in the fruit fly |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued | ||
| FZDE | Discontinued |
Effective date: 20121022 |